Close Menu

licensing agreement

The May 8 settlement resolves all claims and counterclaims relating to noninvasive prenatal testing and pre-implantation genetic screening and diagnosis.

The partners are planning to develop and commercialize UroMap, a urine-based gene-expression test for acute cellular rejection in kidney transplant recipients.

Veracyte has obtained rights to a 52-gene signature developed by Yale researchers to predict disease progression in patients with idiopathic pulmonary fibrosis.

PharmaCyte, which develops therapies for cancer and diabetes, will be responsible for development and commercialization of tests based on the technology.

Biomerica intends to manufacture ELISA test technology licensed from Mt. Sinai. The firm said it has capacity to manufacture 1 million tests per month.

The firm licensed the assay for detecting SARS-CoV-2 from Hackensack Meridian Health and will adapt it for the T2Dx instrument.

The test can be completed in 15 minutes using an app and will be distributed with Scanwell's telehealth partner Lemonaid Health.

The deal aims to create novel products to help diagnostic companies manage risks of interferences in current test designs. 

The deal gives DiaSorin the exclusive rights to TTP's sample-to-answer diagnostic system for human in vitro diagnostic applications.

The PAVmed subsidiary will have the option to license the biomarkers for a year after the completion of a Phase II study evaluating their accuracy.

Pages